Joseph Shulman
Vermögen: 2 Mio $ am 30.06.2026
Vermögen: 2 Mio $ am 30.06.2026
Joseph Shulman is Chief Technical Officer at Rhythm Pharmaceuticals, Inc. since 2022, with employment at the company starting in 2020.
Formerly, Mr. Shulman was Senior Vice President-Technical Operations at RA Pharmaceuticals, Inc. from 2019 to 2020 and Senior Vice President-Global Technical Operations at Novelion Therapeutics, Inc. from 2014 to 2019.
Education includes an MBA from Boston University and an undergraduate degree from the University of Miami.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 11.02.2026 | 18 970 ( 0,03 % ) | 2 Mio $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 27.07.2020 |
| Unternehmen | Position | Ende |
|---|---|---|
| RA PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2020 |
| NOVELION THERAPEUTICS INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2019 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Ra Pharmaceuticals, Inc.
Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of glomerulonephritis, kidney disease and cardiovascular disease | Health Technology |
Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and supplies peptide therapeutics for rare neuroendocrine diseases | Health Technology |
Boston University
Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Miami
University of Miami Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novelion Therapeutics, Inc.
Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets rare disease products, metreleptin and lomitapide | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen